Novel CD4+ Donor Lymphocyte Therapy Shows Promising Remission Rates in High-Risk Myeloid Malignancie | Blood Cancers Today
CD4+ MMUDLI treatment achieved complete remission rates of more than 50% in treatment-refractory myelodysplastic syndrome.
Related Articles
Oncology Regulatory Expertise and Early Guidance (OREEG)
Project Catalyst’s Oncology Regulatory Expertise and Early Guidance (OREEG), is an educational initiative of the Oncology Center of Excellence (OCE),
Public comment – American Society for Radiation Oncology (ASTRO) – American Society for Radiation Oncology (ASTRO)
View the guidelines and practice parameters are available for public comment.
Precision Medicine in AML: An Abundance of Options | Blood Cancers Today
Experts delve deeper into the evolving treatment landscape, focusing on the transformative role of targeted therapies.
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology
FDA Broad Agency Announcement: Frequently Asked Questions for Oncology Researchers
SEER*Explorer Application
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
What are Cancer Vaccines? | Dana-Farber Cancer Institute
Published: May 24, 2021Updated: December 4, 2023Written by: Beth DoughertyMedically Reviewed By: Patrick Ott, MD, PhDKey Takeaways: The goal of cancer vaccines is to spur…
AMPLIFY Data Reveals Advantages of All-Oral BTKi Therapy is Treatment-Naïve CLL | Blood Cancers Today
The phase 3 AMPLIFY study provides evidence that fixed-duration acalabrutinib plus venetoclax may be a valid treatment option for fit patients with treatment-naive CLL.
SurgOnc Today® – Society of Surgical Oncology
SurgOnc Today® is an educational podcast for cancer surgeons from the Society of Surgical Oncology. Each episode features conversations with individuals who are experts within their…
Venetoclax and CLL: How Much TLS Monitoring Is Really Necessary? | Blood Cancers Today
The standard strategy for TLS mitigation is dose escalation and TLS monitoring during dose ramp-up, and there is an ongoing debate on whether the standard…